|
Name |
Octadecane
|
Molecular Formula | C18H38 | |
IUPAC Name* |
octadecane
|
|
SMILES |
CCCCCCCCCCCCCCCCCC
|
|
InChI |
InChI=1S/C18H38/c1-3-5-7-9-11-13-15-17-18-16-14-12-10-8-6-4-2/h3-18H2,1-2H3
|
|
InChIKey |
RZJRJXONCZWCBN-UHFFFAOYSA-N
|
|
Synonyms |
OCTADECANE; n-Octadecane; 593-45-3; Octadecan; TS Paraffin TS 8; N102P6HAIU; 1-(4-Chlorophenyl)-1,3-dihydro-2H-indol-2-one; NSC-4201; Octadecane, 99%; MFCD00009007; 128271-18-1; Octadecane, analytical standard; Octadecane, n-; UNII-N102P6HAIU; Oktadekan; CCRIS 681; NSC 4201; EINECS 209-790-3; AI3-06523; OCTADECANE [INCI]; EC 209-790-3; DTXSID9047172; CHEBI:32926; HSDB 8348; NSC4201; CH3-[CH2]16-CH3; CACTUS NORMAL PARAFFIN TS 8; HY-N6600; LMFA11000581; ZINC59592152; AKOS015903064; Octadecane, purum, >=97.0% (GC); AS-56224; CS-0034329; FT-0699867; O0003; Q150900; 379E5588-B955-4C35-88E0-21E7DF38DE0E
|
|
CAS | 593-45-3 | |
PubChem CID | 11635 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 254.5 | ALogp: | 9.3 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 15 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 0.0 | Aromatic Rings: | 0 |
Heavy Atoms: | 18 | QED Weighted: | 0.269 |
Caco-2 Permeability: | -4.864 | MDCK Permeability: | 0.00000729 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.264 |
30% Bioavailability (F30%): | 0.999 |
Blood-Brain-Barrier Penetration (BBB): | 0.065 | Plasma Protein Binding (PPB): | 98.35% |
Volume Distribution (VD): | 4.074 | Fu: | 1.46% |
CYP1A2-inhibitor: | 0.168 | CYP1A2-substrate: | 0.179 |
CYP2C19-inhibitor: | 0.318 | CYP2C19-substrate: | 0.066 |
CYP2C9-inhibitor: | 0.081 | CYP2C9-substrate: | 0.953 |
CYP2D6-inhibitor: | 0.278 | CYP2D6-substrate: | 0.048 |
CYP3A4-inhibitor: | 0.186 | CYP3A4-substrate: | 0.038 |
Clearance (CL): | 4.465 | Half-life (T1/2): | 0.048 |
hERG Blockers: | 0.263 | Human Hepatotoxicity (H-HT): | 0.007 |
Drug-inuced Liver Injury (DILI): | 0.286 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.03 | Maximum Recommended Daily Dose: | 0.032 |
Skin Sensitization: | 0.957 | Carcinogencity: | 0.031 |
Eye Corrosion: | 0.995 | Eye Irritation: | 0.934 |
Respiratory Toxicity: | 0.466 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000428 | 0.945 | D00AOJ | 0.653 | ||||
ENC000427 | 0.942 | D07ILQ | 0.623 | ||||
ENC000285 | 0.897 | D00FGR | 0.568 | ||||
ENC000379 | 0.885 | D0Z5SM | 0.559 | ||||
ENC000430 | 0.852 | D05ATI | 0.478 | ||||
ENC000423 | 0.827 | D0O1PH | 0.457 | ||||
ENC000486 | 0.825 | D0T9TJ | 0.415 | ||||
ENC000432 | 0.813 | D00STJ | 0.395 | ||||
ENC000521 | 0.783 | D00MLW | 0.388 | ||||
ENC000589 | 0.783 | D0P1RL | 0.352 |